The fact that it can simultaneously suppress two fundamental pathways, mTORC1 in CM and TGFβ1 in cardiac fibroblasts, posits PIP4k2c as a key target for regulating CH and CF in HF patients. Here, TGFB1 is linked to cystic fibrosis.